XMT-2056 is a HER2-targeted antibody-drug conjugate (ADC) consisting of a HER2-targeted antibody conjugated with a stimulator of interferon genes (STING) agonist payload.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.